Portfolio Doubler with Artificial Intelligence: Novo Nordisk, PanGenomic Health, and Pfizer Ignite the Profit Growth in 2025

Novo Nordisk – Reasons for the next growth spurt and stumbling blocks

Danish healthcare giant Novo Nordisk remains at the forefront of global megatrends. The enormous demand for effective treatments for diabetes and obesity continues worldwide. Drivers such as Ozempic and Wegovy are already generating strong sales. Now, momentum is building in the pipeline. The combination drug CagriSema has shown an average weight loss of over 22% in studies. The new active ingredient Amycretin, with up to 24% weight loss in early studies, could also become a blockbuster in the long term. Such innovations consolidate Novo's leading position in a market with huge, still far from exhausted potential. The biggest challenge in recent years has been supply bottlenecks.

The Company is investing around USD 9 billion in expanding production by 2025. This includes new active ingredient production facilities, the acquisition of strategic sites, and the construction of a large-scale plant in North Carolina. The goal is to massively increase supply security for blockbusters such as Wegovy and Ozempic. This should enable the forecast revenue growth of 13-21% in the current year to be achieved. The first quarter significantly exceeded expectations with a jump in revenue of almost 27% and a 20% increase in profit. Operating margins remain impressively high, and strong cash flow is financing the expansion without excessive debt.

Of course, there are risks. Competition, particularly from Eli Lilly's Zepbound, has intensified. In the US, generic products (compounding) are putting short-term pressure on prices and market share. Political uncertainties, such as those surrounding drug prices in the US, remain a Sword of Damocles. In addition, the surprising departure of the CEO in May 2025 is causing short-term leadership uncertainty. These factors could slow the pace of growth - even though the long-term growth story remains intact. The share is currently available for EUR 62.49.

PanGenomic Health – Tailwind from megatrends and US politics

The market for digital healthcare is booming, driven by the longevity hype and exploding treatment costs in the US. PanGenomic Health has its finger on the pulse here. The Canadian company offers apps for personalized prevention that are cost-effective alternatives to the traditional healthcare system. It is important to note that the new US administration under Health Secretary Robert F. Kennedy Jr. explicitly promotes preventive approaches and natural treatments. This political support will greatly facilitate PanGenomic's entry into the North American market. The Company has declared 2025 the "Year of Growth" and is fully focused on this expansion.

Unlike biotech companies, which have to pump billions into research, PanGenomic cleverly leverages existing scientific knowledge. At its core is the Nustasis AI platform, which controls three applications. The NARA app specializes in personalized recommendations for natural remedies, using genetic information and lifestyle tracking data. The Mindleap app addresses mental health and resilience and integrates telemedicine features to manage stress digitally. MUJN is a website that focuses on neurobiomarker-based therapy adjustments. The key feature: The system seamlessly links data collection, AI analysis, and product deliveries such as dietary supplements. This generates revenue through subscriptions, e-commerce, and diagnostics with minimal development costs and without lengthy approval processes.

The business model is scalable. The digital health market in North America is estimated to be worth over USD 700 billion by 2030. On June 20, the Company announced that the early expiration of warrants on July 9, 2025, is expected to generate approximately CAD 730,000. This liquidity comes at just the right time to accelerate US expansion. With a current market capitalization in the single-digit millions, even moderate commercial success in North America would have a noticeable leverage effect. The share price currently stands at CAD 0.68.

Pfizer – The turnaround is gaining momentum

After a period of consolidation, there are many indications that Pfizer could take decisive steps out of the trough in 2025. The key lies in a newly sharpened strategy. Instead of relying on past successes, the pharmaceutical giant is consistently focusing on its innovative strength. The oncology division, which has been massively strengthened by the Seagen acquisition, is developing into a driving force. With several promising candidates in the late pipeline, including new cancer drugs and an established RSV vaccine, Pfizer has the potential to launch new blockbusters in the coming years. These products could offset declining revenues from older drugs and generate new growth.

Pfizer is showing financial discipline. An ambitious cost-cutting program is expected to free up around USD 4.5 billion by the end of 2025. These funds will be reinvested in promising areas such as mRNA technology, gene therapies, and further strengthening of the oncology division. At the same time, the balance sheet remains robust. Strong free cash flow continues to support an attractive dividend, currently around 7%, and provides scope for strategic investments. With its forecast for 2025, which envisages revenue of USD 61-64 billion and earnings per share of USD 2.80-3.00, the Company's management is signaling confidence, supported by ongoing efficiency gains and the expected ramp-up of new products.

Of course, the Company still faces challenges. The "patent cliff" is real. Revenues from key products such as Eliquis will come under noticeable pressure from generics in the coming years. Political uncertainties, particularly surrounding vaccine policy and drug prices in the US, pose additional risks. The successful launch of new drugs from the pipeline is crucial to closing these gaps. If Pfizer manages to bridge this gap – and its current research and cost efficiency efforts suggest that it will – 2025 could be the year when the long-awaited upturn becomes tangible. The share price is currently USD 23.97.

The healthcare sector will turbocharge profits in 2025 with AI-driven innovation. Novo Nordisk is driving growth with strong diabetes/obesity blockbusters and massive investments, even if competition and leadership changes are dampening the short-term outlook. PanGenomic Health is accelerating its market entry thanks to political tailwinds in the US and its scalable AI model for prevention, with even moderate commercial success having a noticeable leverage effect. Pfizer is successfully countering the patent cliff with a focused oncology pipeline, strict cost-cutting, and mRNA investments, effectively building a bridge to its turnaround.